24
Participants
Start Date
September 2, 2022
Primary Completion Date
July 8, 2024
Study Completion Date
July 8, 2024
Suvratoxumab
Monoclonal antibody
Placebo
Placebo contains only excipients
Fra06, Limoges
Research Site Bel03, Haine-Saint-Paul
Research Site Bel02, Ottignies
Research Site Bel05, Yvoir
Research Site Fra05, Argenteuil
Research Site Fra16, La Roche-sur-Yon
Research Site Fra10, Le Mans
Research Site Fra08, Lille
Research Site Fra07, Orléans
Research Site Fra15, Pierre-Bénite
Research Site Fra12, Tours
Research Site Fra03, Trévenans
Research Site GRC01, Larissa
Research Site ISR03, Haifa
Research Site ISR05, Holon
Research Site ISR01, Ramat Gan
Research Site ISR06, Safed
Research Site NLD01, Enschede
Research Site NLD03, Heerlen
Research Site NLD02, Utrecht
Research Site SPA04, Barcelona
Research Site SPA01, Córdoba
Research Site SPA07, Madrid
Research Site SPA08, Santander
Research Site SPA06, Santiago de Compostela
Research Site SPA03, Terrassa
Research Site SPA05, Valencia
Lead Sponsor
Aridis Pharmaceuticals, Inc.
INDUSTRY